Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025

Provided By GlobeNewswire

Last update: Apr 30, 2025

CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will participate at the upcoming BofA Securities Health Care Conference 2025 on Wednesday, May 14, 2025, at the Encore Hotel, Las Vegas, Nevada.

CPRX Latest News and Analysis

6 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Rare Combination of Growth and Value

CATALYST PHARMACEUTICALS (CPRX) offers strong growth, solid profitability, and an attractive valuation, making it a standout in biotech.

9 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for CANSLIM Investors

CATALYST PHARMACEUTICALS (CPRX) meets CANSLIM criteria with strong earnings growth, high relative strength, and solid fundamentals. A technical uptrend and reasonable valuation add to its appeal.

11 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Growth Investors

CATALYST PHARMACEUTICALS INC (CPRX) meets key growth criteria from Louis Navellier’s strategy, with strong earnings, revenue growth, and solid financial health. A detailed analysis highlights its potential for investors.

20 days ago - ChartmillCATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) – A Strong Contender for Quality Investors

Catalyst Pharmaceuticals (CPRX) shows strong fundamentals, high profitability, and zero debt, making it a compelling choice for quality investors. The stock trades at reasonable valuations with solid growth prospects.

Follow ChartMill for more